# A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck

> **NCT03620123** · PHASE2 · COMPLETED · sponsor: **AIO-Studien-gGmbH** · enrollment: 54 (actual)

## Conditions studied

- Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Carcinoma, Squamous Cell of Head and Neck

## Interventions

- **DRUG:** Nivolumab and Ipilimumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT03620123
- **Lead sponsor:** AIO-Studien-gGmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-16
- **Primary completion:** 2021-06-20
- **Final completion:** 2022-06-19
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2022-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03620123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03620123, "A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03620123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*